Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

doi:10.4240/wjgs.v16.i3.700

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1179)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

101

HTML

582

Figures (1-2)

106

Tables (1-3)

103

Sum=892

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

192

Sum=244

Mar 27, 2024 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Mar 27, 2024; 16(3): 700-709
Published online Mar 27, 2024. doi: 10.4240/wjgs.v16.i3.700

Open in New Tab Full Size Figure Download Figure

Figure 1 Comparison of immunotherapy efficacy in gastric cancer patients with liver metastasis and those without liver metastasis. ORR: Objective response rate; DCR: Disease control rate; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressing disease.

Open in New Tab Full Size Figure Download Figure

Figure 2 Progression-free survival and overall survival curves of patients with advanced gastric cancer with liver metastasis and without liver metastasis. A: Progression-free survival curves; B: Overall survival curves. PFS: Progression-free survival; OS: Overall survival.

Citation: Liu K, Wu CX, Liang H, Wang T, Zhang JY, Wang XT. Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis. World J Gastrointest Surg 2024; 16(3): 700-709
URL: https://www.wjgnet.com/1948-9366/full/v16/i3/700.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i3.700